Challenges in treating older patients with acute myeloid leukemia.

Journal of Oncology
Lagadinou D EleniSpyridonidis Alexandros

Abstract

Whereas in younger patients diagnosed with acute myeloid leukemia (AML) treatment is straightforward and the goal is cure, the optimal treatment decision for older adults remains highly controversial. Physicians need to determine whether palliation, "something" beyond palliation, intensive therapy, or an investigational therapy is the most appropriate treatment option. This requires understanding of the biology and risk profile of the AML, clinical judgment in evaluating the functional status of the patient, communication skills in understanding the patient's wishes and social background, and medical expertise in available therapies. The physician has to accurately inform the patient about (a) the unique biological considerations of his leukemia and his prognosis; (b) the risks and benefits of all available treatment options; (c) novel therapeutic approaches and how the patient can get access to these treatments. Last but not least, he has to recommend a treatment. This paper tries to discuss each of these issues.

References

Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM A Friedman
Aug 20, 1987·The New England Journal of Medicine·P J FialkowR Veith
Mar 13, 1987·Deutsche medizinische Wochenschrift·H Hempfling
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W HiddemannT Büchner
Jun 13, 2002·Reviews in Clinical and Experimental Hematology·Thomas BüchnerUNKNOWN German AML Co-Operative Group
Jul 19, 2002·Archives of Internal Medicine·Joseph MenzinRajiv Mallick
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter L GreenbergJacob M Rowe
May 5, 2005·Blood·Martin S TallmanJacob M Rowe
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Edvardas KaminskasUNKNOWN FDA
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ute HegenbartRainer Storb
Jan 13, 2006·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellMartin S Tallman
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Apr 11, 2006·Reproductive Biology and Endocrinology : RB&E·Ann E Drummond
Oct 7, 2006·Cost Effectiveness and Resource Allocation : C/E·Franz P Hessel

❮ Previous
Next ❯

Citations

Jan 26, 2016·Chemical Biology & Drug Design·Sorina SuarasanSimion Astilean
Sep 11, 2016·Journal of Hematology & Oncology·Rosalia de Necochea-CampionChien-Shing Chen
Mar 18, 2021·Journal of Oncology·Itzen Aguiñiga-SánchezEdelmiro Santiago-Osorio

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.